A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants With Systemic Lupus Erythematosus

Inclusion Criteria: * The participant could, in the opinion of the Investigator, benefit from long-term dapirolizumab pegol (DZP) treatment * The participant completed one of the parent studies within 4 weeks prior to entry to this study Exclusion Criteria: \- Study participant has any medical or psychiatric condition (including conditions due to neuropsychiatric systemic lupus erythematosus (SLE)) that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study. This includes study participants with a life-threateni…